$PTGX
Protagonist Therapeutics, Inc

2023 Q2 Form 10-Q Financial Statement

#000155837023008137 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.172M $8.605M
YoY Change 19.26% -18.16%
% of Gross Profit
Research & Development $33.18M $27.42M
YoY Change -4.13% -24.51%
% of Gross Profit
Depreciation & Amortization $237.0K $248.0K
YoY Change -8.49% -0.4%
% of Gross Profit
Operating Expenses $42.35M $36.02M
YoY Change 0.12% -23.09%
Operating Profit -$42.35M -$36.02M
YoY Change 2.2% 70.63%
Interest Expense $3.913M $2.491M
YoY Change 708.47% 1382.74%
% of Operating Profit
Other Income/Expense, Net -$19.00K -$195.0K
YoY Change -75.64% -1600.0%
Pretax Income -$38.46M -$33.73M
YoY Change -6.28% 61.13%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$38.46M -$33.73M
YoY Change -6.28% 61.13%
Net Earnings / Revenue
Basic Earnings Per Share -$0.68 -$0.67
Diluted Earnings Per Share -$0.68 -$0.67
COMMON SHARES
Basic Shares Outstanding 57.25M 51.28M
Diluted Shares Outstanding 56.78M 50.57M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $313.4M $230.8M
YoY Change 7.37% -24.41%
Cash & Equivalents $235.4M $127.7M
Short-Term Investments $78.02M $103.1M
Other Short-Term Assets $3.490M $4.926M
YoY Change -61.43% -36.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables $11.00K
Total Short-Term Assets $316.9M $235.7M
YoY Change 4.15% -30.97%
LONG-TERM ASSETS
Property, Plant & Equipment $1.263M $1.341M
YoY Change -35.63% -35.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $225.0K $225.0K
YoY Change 0.0% 0.0%
Total Long-Term Assets $3.525M $4.122M
YoY Change -43.24% -39.15%
TOTAL ASSETS
Total Short-Term Assets $316.9M $235.7M
Total Long-Term Assets $3.525M $4.122M
Total Assets $320.5M $239.9M
YoY Change 3.21% -31.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.573M $4.021M
YoY Change 223.87% -43.83%
Accrued Expenses $19.37M $16.59M
YoY Change -46.56% -49.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.40M $23.23M
YoY Change -34.15% -46.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $462.0K
YoY Change -100.0% -84.91%
Total Long-Term Liabilities $0.00 $462.0K
YoY Change -100.0% -84.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.40M $23.23M
Total Long-Term Liabilities $0.00 $462.0K
Total Liabilities $26.40M $23.69M
YoY Change -37.94% -49.07%
SHAREHOLDERS EQUITY
Retained Earnings -$608.9M -$570.5M
YoY Change 29.2% 32.58%
Common Stock $903.2M $786.8M
YoY Change 22.05% 7.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $294.1M $216.2M
YoY Change
Total Liabilities & Shareholders Equity $320.5M $239.9M
YoY Change 3.21% -31.13%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$38.46M -$33.73M
YoY Change -6.28% 61.13%
Depreciation, Depletion And Amortization $237.0K $248.0K
YoY Change -8.49% -0.4%
Cash From Operating Activities -$26.24M -$34.35M
YoY Change 92.43% -8.81%
INVESTING ACTIVITIES
Capital Expenditures $176.0K $10.00K
YoY Change -160.69% -96.34%
Acquisitions
YoY Change
Other Investing Activities $25.94M $9.836M
YoY Change -25.94% -334.02%
Cash From Investing Activities $25.76M $9.826M
YoY Change -25.83% -319.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 108.2M 26.46M
YoY Change 15807.65% 56.35%
NET CHANGE
Cash From Operating Activities -26.24M -34.35M
Cash From Investing Activities 25.76M 9.826M
Cash From Financing Activities 108.2M 26.46M
Net Change In Cash 107.7M 1.942M
YoY Change 394.49% -107.71%
FREE CASH FLOW
Cash From Operating Activities -$26.24M -$34.35M
Capital Expenditures $176.0K $10.00K
Free Cash Flow -$26.41M -$34.36M
YoY Change 97.93% -9.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
584000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
584000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1255000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-358000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
248000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
249000
CY2023Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
194000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
41000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
381000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
5559000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-47000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-519000
CY2022Q1 ptgx Due To Related Party Additions
DueToRelatedPartyAdditions
330000
CY2022Q1 ptgx Due To Related Party Deductions
DueToRelatedPartyDeductions
849000
CY2022Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
380000
CY2023Q1 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
0
CY2022Q1 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
13000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
42000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4926000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5712000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.17
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
128722
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
13.49
CY2023Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Forfeited
StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
148693
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
26.21
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8161844
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.14
CY2022Q1 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2023Q1 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49339252
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51440503
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001377121
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-37852
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
PROTAGONIST THERAPEUTICS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0505495
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
7707 Gateway Boulevard, Suite 140
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Newark
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94560-1160
CY2023Q1 dei City Area Code
CityAreaCode
510
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
474-0170
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
PTGX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
57251254
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
127686000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
239858000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
247928000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
25722000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
125744000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
103073000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
111611000
CY2023Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
51000
CY2022Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
10000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4926000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5712000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
235736000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
243077000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1341000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1565000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
225000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
225000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2556000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3061000
CY2023Q1 us-gaap Assets
Assets
239858000
CY2022Q4 us-gaap Assets
Assets
247928000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4021000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3640000
CY2023Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
22000
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
69000
CY2023Q1 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
16587000
CY2022Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
24955000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2599000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2515000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
23229000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31179000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
462000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1141000
CY2023Q1 us-gaap Liabilities
Liabilities
23691000
CY2022Q4 us-gaap Liabilities
Liabilities
32320000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51440503
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49339252
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
786768000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
752722000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-122000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-359000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-570480000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-536755000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
216167000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
215608000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27416000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36318000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8605000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10515000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
36021000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
46833000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-36021000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21111000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2491000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
168000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-195000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-33725000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20930000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50573650
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50573650
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48752548
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48752548
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-33725000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20930000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
194000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
95000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
43000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-268000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33488000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21103000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
215608000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
24302000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2261000
CY2023Q1 ptgx Shares Withheld For Net Settlements Of Tax Withholding Upon Vesting Of Restricted Stock Units
SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits
100000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7584000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
237000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-33725000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
216167000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
300021000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14553000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2558000
CY2022Q1 ptgx Shares Withheld For Net Settlements Of Tax Withholding Upon Vesting Of Restricted Stock Units
SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits
186000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5935000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-173000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20930000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
301778000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-33725000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-20930000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7584000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M26D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
63300000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
23584000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-787000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5935000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3935198
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1279000
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-8383000
CY2022Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-5110000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-833000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
674000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
654000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34347000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37666000
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
28060000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
55832000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
37896000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
51629000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
273000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9826000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4476000
CY2023Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
24302000
CY2022Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
14553000
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2261000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2558000
CY2023Q1 ptgx Shares Withheld For Net Settlement Of Tax Withholding Upon Vesting Of Restricted Stock Units
SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits
100000
CY2022Q1 ptgx Shares Withheld For Net Settlement Of Tax Withholding Upon Vesting Of Restricted Stock Units
SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits
186000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26463000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16925000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1942000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25188000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125969000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
123890000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
127911000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98702000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
15000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
235000
CY2022Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
25000
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 ptgx Cash Cash Equivalents And Marketable Securities Carrying Value
CashCashEquivalentsAndMarketableSecuritiesCarryingValue
230800000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-570500000
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
1566000
CY2022Q1 ptgx Contract With Customer Asset Additions
ContractWithCustomerAssetAdditions
25150000
CY2022Q1 ptgx Contract With Customer Asset Deduction
ContractWithCustomerAssetDeduction
1566000
CY2022Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
25150000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1601000
CY2022Q1 ptgx Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
25658000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development activities, stock-based compensation, income taxes, marketable securities and leases. Estimates related to revenue recognition include actual costs incurred versus total estimated costs of the Company’s deliverables to determine percentage of completion in addition to the application and estimates of potential revenue constraints in the determination of the transaction price under its license and collaboration agreements. Management bases these estimates on historical and anticipated results, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. Actual results could differ materially from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the prolonged nature of the COVID-19 pandemic, military conflict between Ukraine and Russia, rising tensions between China and Taiwan and inflationary pressures, there has been uncertainty and disruption in the global economy and financial markets. The Company has taken into consideration any known impacts in its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the issuance of this report. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.</p>
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
127686000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98477000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
225000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
225000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
127911000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98702000
CY2022Q1 ptgx Contract With Customer Liability Deduction
ContractWithCustomerLiabilityDeduction
26491000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
768000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
899000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.82
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1018000
CY2023Q1 ptgx Cash Equivalents And Marketable Securities Amortized Cost
CashEquivalentsAndMarketableSecuritiesAmortizedCost
223970000
CY2023Q1 ptgx Cash Equivalents And Marketable Securities Gross Unrealized Gain
CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
75000
CY2023Q1 ptgx Cash Equivalents And Marketable Securities Gross Unrealized Loss
CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
86000
CY2023Q1 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
223959000
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
120886000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
103073000
CY2023Q1 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
223959000
CY2022Q4 ptgx Cash Equivalents And Marketable Securities Amortized Cost
CashEquivalentsAndMarketableSecuritiesAmortizedCost
232556000
CY2022Q4 ptgx Cash Equivalents And Marketable Securities Gross Unrealized Gain
CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
27000
CY2022Q4 ptgx Cash Equivalents And Marketable Securities Gross Unrealized Loss
CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
81000
CY2022Q4 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
232502000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
120891000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
111611000
CY2022Q4 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
232502000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
103100000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
111600000
CY2023Q1 ptgx Current Contractual Maturities Maximum Period
CurrentContractualMaturitiesMaximumPeriod
P1Y
CY2022 ptgx Current Contractual Maturities Maximum Period
CurrentContractualMaturitiesMaximumPeriod
P1Y
CY2022Q1 us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0
CY2023Q1 us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0
CY2023Q1 ptgx Prepaid Manufacturing Of Clinical Materials
PrepaidManufacturingOfClinicalMaterials
1492000
CY2022Q4 ptgx Prepaid Manufacturing Of Clinical Materials
PrepaidManufacturingOfClinicalMaterials
2746000
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
1401000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1417000
CY2023Q1 ptgx Prepaid Licenses
PrepaidLicenses
542000
CY2022Q4 ptgx Prepaid Licenses
PrepaidLicenses
489000
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1491000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M23D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
30800000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8161844
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
17.14
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y8M26D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
63300000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6833000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6819000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5492000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5254000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1341000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1565000
CY2023Q1 ptgx Accrued Clinical And Research Related Expenses Current
AccruedClinicalAndResearchRelatedExpensesCurrent
13108000
CY2022Q4 ptgx Accrued Clinical And Research Related Expenses Current
AccruedClinicalAndResearchRelatedExpensesCurrent
19109000
CY2023Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2080000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4967000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1065000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
464000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
334000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
415000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16587000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24955000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6240509
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.03
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2198750
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.05
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7584000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5935000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
66800000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-33725000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20930000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50573650
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50573650
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48752548
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48752548
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12000454
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10291682

Files In Submission

Name View Source Status
ptgx-20230331_def.xml Edgar Link unprocessable
ptgx-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001558370-23-008137-index-headers.html Edgar Link pending
0001558370-23-008137-index.html Edgar Link pending
0001558370-23-008137.txt Edgar Link pending
0001558370-23-008137-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ptgx-20230331.xsd Edgar Link pending
ptgx-20230331x10q.htm Edgar Link pending
ptgx-20230331x10q007.jpg Edgar Link pending
ptgx-20230331xex31d1.htm Edgar Link pending
ptgx-20230331xex31d2.htm Edgar Link pending
ptgx-20230331xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
ptgx-20230331_cal.xml Edgar Link unprocessable
ptgx-20230331_lab.xml Edgar Link unprocessable
ptgx-20230331x10q_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending